Higher-Dose Statins Linked to Moderate Increase in Diabetes Risk.

[Argirios Argiriou]

Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases.
BMJ 2014; 348 doi: Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος (Published 29 May 2014)
Cite this as: BMJ 2014;348:g3244


Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος

και  το σχόλιο του Journal Watch:
Higher doses of statins are associated with greater risk for incident diabetes than lower doses, according to a BMJ study.

Using healthcare databases from Canada, the UK, and the US, researchers identified 137,000 patients who were prescribed statins after hospitalization for a major cardiovascular event. At 2 years, patients prescribed a higher-dose statin (rosuvastatin, 10 mg and up; atorvastatin, 20 mg and up; simvastatin, 40 mg and up) had a 15% higher rate of new diabetes diagnoses than lower-dose statin users. Incidence rates were highest in the first 4 months.

Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος